<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00686972</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00004876</org_study_id>
    <nct_id>NCT00686972</nct_id>
  </id_info>
  <brief_title>The Effect of Surgically Induced Weight Loss on Endocrine Function, Cardiovascular Function and Body Composition</brief_title>
  <official_title>The Effect of Surgically Induced Weight Loss on Endocrine Function, Cardiovascular Function and Body Composition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to evaluate changes in sugar, metabolism, heart function and
      changes in body composition as patients lose weight following bariatric surgery. The
      investigators will compare improvements of the above changes as a function of the four
      different types of bariatric surgery. The investigators believe the most beneficial and
      safest procedure will be the Roux-en-Y.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will also examine the response of the pancreas (the insulin-producing organ) to a
      sugar load, as well as to a hormone called Glucagon Like Peptide 1 (GLP-1), which is released
      from your gut to maximally stimulate your pancreas. The release of this hormone increases
      when you eat food and it causes the pancreas to release more insulin than does sugar alone.
      Volunteers will have 22 visits over a two year period. Only people having Roux-en-Y gastric
      bypass surgery, gastric sleeve surgery, duodenal switch gastric surgery or lap-band/gastric
      banding surgery may join. Seventy volunteers will be recruited to take part in this study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI left JHU
  </why_stopped>
  <start_date type="Actual">May 2007</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Secretion</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Bariatric Surgery</condition>
  <arm_group>
    <arm_group_label>GLP-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 ng/kg/min, IV for 1 hour during each clamp study (7) over 2 year period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLP-1</intervention_name>
    <description>5 ng/kg/min, IV for 1 hour during each clamp study (7) over 2 year period.</description>
    <arm_group_label>GLP-1</arm_group_label>
    <other_name>Glucagon-like Peptide-1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female volunteers 21-65 years.

          -  BMI &gt; 40.

          -  Preoperative hematocrit level of at least 34% for women and 38% for men.

          -  Postoperative hematocrit level of at least 34% for women and 36% for men.

        Exclusion Criteria:

          -  Volunteers whose hematocrit level does not meet the above criteria.

          -  Pregnant and or lactating females.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dariush Elahi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2008</study_first_submitted>
  <study_first_submitted_qc>May 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2008</study_first_posted>
  <results_first_submitted>May 1, 2017</results_first_submitted>
  <results_first_submitted_qc>June 1, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 2, 2017</results_first_posted>
  <last_update_submitted>June 1, 2017</last_update_submitted>
  <last_update_submitted_qc>June 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bariatric Surgery</keyword>
  <keyword>Glucose Regulation</keyword>
  <keyword>Cardiac Function</keyword>
  <keyword>Body Composition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
    <mesh_term>Glucagon</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Glucagon Like Peptide 1 -GLP-1</title>
          <description>5 ng/kg/min, IV for 1 hour during each clamp study (7) over 2 year period.
GLP-1: 5 ng/kg/min, IV for 1 hour during each clamp study (7) over 2 year period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>P.I, Left institution. Study terminated</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GLP-1</title>
          <description>5 ng/kg/min, IV for 1 hour during each clamp study (7) over 2 year period.
GLP-1: 5 ng/kg/min, IV for 1 hour during each clamp study (7) over 2 year period.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="51"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt;=21 and &lt;=65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Insulin Secretion</title>
        <time_frame>2 years</time_frame>
        <population>The PI left the institution and this study was terminated due to noncompliance with our Institutional Review Board. Outcome measure data, if collected, is unknown since no data are available.</population>
        <group_list>
          <group group_id="O1">
            <title>GLP-1</title>
            <description>5 ng/kg/min, IV for 1 hour during each clamp study (7) over 2 year period.
GLP-1: 5 ng/kg/min, IV for 1 hour during each clamp study (7) over 2 year period.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Secretion</title>
          <population>The PI left the institution and this study was terminated due to noncompliance with our Institutional Review Board. Outcome measure data, if collected, is unknown since no data are available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The PI left the institution and this study was terminated due to noncompliance with our Institutional Review Board. Adverse Event data, if collected, is unknown since no data are available.</desc>
      <group_list>
        <group group_id="E1">
          <title>GLP-1</title>
          <description>5 ng/kg/min, IV for 1 hour during each clamp study (7) over 2 year period.
GLP-1: 5 ng/kg/min, IV for 1 hour during each clamp study (7) over 2 year period.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Johns Hopkins University Clinical Trials Program</name_or_title>
      <organization>Johns Hopkins University School of Medicine</organization>
      <phone>410-550-6484</phone>
      <email>registerclinicaltrials@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

